You are here: Industry Insights > melanoma

News List

BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients pharmatimes
May 25, 2021
Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) combination has demonstrated ‘durable improvement in survival’, according to new long-term data from a Phase III trial.
BMS’ Opdivo plus LAG-3 antibody relatlimab show promise in melanoma pharmatimes
March 31, 2021
Bristol Myers Squibb (BMS) has revealed top-line data from a Phase II/III trial evaluating its PD-1 inhibitor Opdivo plus its investigational anti-LAG-3 antibody relatlimab in previously untreated metastatic or unresectable melanoma.
Sirtex Medical announces collaboration update with OncoSec Medical prnasia
January 20, 2021
Sirtex Medical US Holdings, Inc. announced an advancement in its strategic collaboration with OncoSec Medical, Inc. relating to OncoSec's lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.
Scientists Engineer DNA-based Nanotechnology to Stimulate Potent Antitumor Immune Responses in Preclinical Models The Wistar Institute
September 24, 2020
Researchers designed DLnano-vaccines displaying 60 copies of protein parts derived from the melanoma-specific antigens Trp2 and Gp100 and tested these in mouse models of melanoma.
Novartis’ Tafinlar plus Mekinist shows long-term benefit in advanced melanoma pharmatimes
September 18, 2020
A combination of Novartis’ cancer meds Tafinlar (dabrafenib) and Mekinist (trametinib) has demonstrated long-term benefit in advanced melanoma patients after five years of treatment.
OncoSec Announces Initiation of aStudy to Evaluate Melanoma Treatment americanpharmaceuticalreview
August 31, 2020
OncoSec Medical Incorporated announced the commencement of an investigator-initiated Phase 2 study led by Senior Member and Professor Ahmad A. Tarhini, M.D., Ph.D. of the H. Lee Moffitt Cancer Center and Research Institute and ...
Novartis' melanoma combo fails in PhIII pharmatimes
August 24, 2020
Novartis has announced that its investigational immunotherapy spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) failed to improve progression-free survival in patients with advanced melanoma.
Skin cancer deaths rocket 70% since the 1970s pharmatimes
August 21, 2020
Melanoma skin cancer deaths have shot up in the UK rising two and half times since the 1970s, according to figures released by Cancer Research UK.
Roche gets US FDA approval for Tecentriq combo to treat advanced melanoma expresspharma
August 03, 2020
The approval is based on results from the Phase III IMspire150 study, in which the addition of Tecentriq to Cotellic and Zelboraf helped people live longer without disease worsening or death.
Scientists double understanding of genetic risk of melanoma expresspharma
April 29, 2020
Melanoma is a sometimes-deadly skin cancer, with an estimated 350,000 cases worldwide in 2015, resulting in nearly 60,000 deaths.

Previous page 1 2 3 4 5 6 7 Next page